Key Facts
Major U.S. corporations, including Pfizer and Alphabet, are increasingly turning to euro-denominated borrowing at an unprecedented pace. This shift is driven by concerns over market instability in the U.S., exacerbated by former President Donald Trump’s tariff policies, which have prompted companies to seek alternative funding sources. According to Bloomberg data, the issuance of euro-denominated bonds by U.S. companies, known as reverse Yankee bonds, has surged by 35% year-over-year in 2025, reaching €83 billion (approximately $90 billion). These bonds now account for 14% of all corporate bonds issued in Europe.
The trend gained momentum after Trump’s unilateral tariff announcements in April, which disrupted markets. Additionally, Moody’s downgraded the U.S. credit rating from its highest level on May 16, further highlighting concerns about the country’s financial stability. Historically, the U.S. corporate bond market has been a primary investment destination for asset managers. However, factors such as volatile dollar fluctuations, high U.S. Treasury yields, and concerns over government debt burdens are prompting a gradual shift toward European markets.
Andrew Menzies, Head of Bond Capital Markets at Société Générale, noted that the growing depth of the European market is a key factor. He highlighted that large-scale issuances, once exclusive to the U.S., are now being absorbed with relative ease in Europe. The eurozone’s capital market expansion aligns with the region’s efforts to strengthen its financial ecosystem.
The cost advantage of euro-denominated bonds is another significant driver. The average yield on euro-denominated corporate bonds is 3.18%, compared to 5.3% for dollar-denominated bonds. This yield gap, the largest in three years, makes euro bonds particularly attractive for companies operating in Europe without the need to convert funds back to dollars. For instance, Alphabet issued €6.75 billion in euro bonds with a 3.375% coupon in May, just a day after issuing $5 billion in dollar bonds with a 4.5% coupon.
Kaspar Hense, a portfolio manager at RBC BlueBay, emphasized that the U.S.’s high debt levels and fiscal deficits are keeping Treasury yields elevated, increasing borrowing costs for households and businesses. As foreign investment in the U.S. slows, companies are likely to continue exploring euro-denominated funding options.
Summary
Major U.S. corporations, including Pfizer and Alphabet, are increasingly issuing euro-denominated bonds, known as reverse Yankee bonds, to mitigate risks associated with U.S. market instability. This trend has accelerated following former President Donald Trump’s tariff policies and Moody’s downgrade of the U.S. credit rating in May 2025. Bloomberg data reveals a 35% year-over-year increase in euro bond issuance by U.S. companies, reaching €83 billion ($90 billion) and accounting for 14% of all corporate bonds issued in Europe.
The European bond market’s growing depth and lower borrowing costs are key drivers. Euro-denominated corporate bonds yield an average of 3.18%, significantly lower than the 5.3% yield for dollar-denominated bonds. For example, Alphabet issued €6.75 billion in euro bonds with a 3.375% coupon, compared to $5 billion in dollar bonds with a 4.5% coupon.
Experts, including Andrew Menzies of Société Générale, highlight Europe’s increasing capacity to absorb large-scale issuances. Kaspar Hense of RBC BlueBay notes that high U.S. debt levels and fiscal deficits are keeping Treasury yields elevated, prompting companies to explore more cost-effective funding options in Europe.
